New cocktail of drugs aims to wipe out aggressive breast cancer before surgery
NCT ID NCT07187674
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (olaparib), and chemotherapy (paclitaxel) given before surgery to 20 women with early, high-risk triple negative breast cancer that has a specific DNA repair defect (HRD positive). The goal is to see if this approach can eliminate all cancer cells in the breast and lymph nodes by the time of surgery. The study is exploratory and will also monitor safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab, tuvonralimab, olaparib, and paclitaxel
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for a hard-to-treat breast cancer type, potentially improving the chance of no cancer remaining after surgery.
What could go wrong
This is a very early, small study with only 20 participants, so results may not apply broadly. The combination of drugs may cause significant side effects, and it is not yet known if it works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••